[usPropHeader] Error loading user control: The file '/CMSWebParts/WK.HLRP/LNC/LNCProductHeader.ascx' does not exist.

Authors

  1. Dalal, Kavitha S. PharmD
  2. Bridgeman, Mary Barna PharmD, BCPS, BCGP

Article Content

CAN YOU IDENTIFY these oncology medications? To find out, match each brand name in Section I with its generic name and description in Section II.

 

Section I

______ 1. Poteligeo (Kyowa Kirin)

 

______ 2. Erleada (Janssen)

 

______ 3. Mektovi (Array BioPharma)

 

Section II

a. mogamulizumab-kpkc. Designated as a CC chemokine receptor type 4-directed monoclonal antibody, this drug is indicated to treat adults with relapsed or refractory mycosis fungoides or Sezary syndrome after at least one prior systemic therapy. It is administered I.V. over at least 60 minutes on days 1, 8, 15, and 22 of the first 28-day cycle and on days 1 and 15 of each subsequent cycle. Because life-threatening infusion reactions and dermatologic toxicity are possible, premedication with diphenhydramine and acetaminophen for the first infusion is recommended.

 

b. apalutamide. Administered orally, this androgen receptor inhibitor is used to treat nonmetastatic, castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. Patients who have not had bilateral orchiectomy should receive a gonadotropin-releasing hormone analogue concurrently. In clinical trials, some patients experienced fractures and falls, so assess patients for fall risk.

 

c. binimetinib. This oral kinase inhibitor is indicated in combination with encorafenib to treat unresectable or metastatic melanoma with a BRAF V600E or V600K mutation confirmed with an FDA-approved test. The most common adverse reactions include fatigue, nausea, vomiting, and abdominal pain. Educate patients about possible serious adverse reactions such as cardiomyopathy, venous thromboembolism, interstitial lung disease, hemorrhage, and ocular toxicities.

 

Answers: 1a, 2b, 3c